For older adults, influenza remains a genuine threat despite decades of vaccination programs — and the conventional high-dose and adjuvanted shots currently recommended for those 65 and up still leave meaningful gaps in protection. An emerging mRNA-based influenza vaccine platform may be narrowing those gaps in ways that matter clinically, making this comparison particularly timely as formulation decisions for coming seasons are debated.
Using an anchored indirect treatment comparison — a methodologically accepted technique when head-to-head trial data are absent — researchers applied the Bucher method to bridge findings from the pivotal mRNA-1010-P304 clinical trial and a large real-world Optum insurance claims dataset covering U.S. adults aged 65 and older. Standard-dose egg-based influenza vaccine served as the common anchor linking the two data sources. To correct for population-level differences across these sources, the team employed target trial emulation and inverse probability weighting. The primary outcome was medically attended influenza infection during the 2024–2025 U.S. influenza season, with multiple sensitivity analyses testing alternative outcome definitions and weighting strategies.
The indirect comparison methodology here is worth scrutinizing carefully. Anchored ITCs are widely used in health technology assessment but carry structural limitations: they assume homogeneity of treatment effects across the populations being bridged, an assumption that can break down when the clinical trial and real-world cohorts differ substantially in frailty, comorbidity burden, or circulating strain exposure. The researchers addressed this with inverse probability weighting, but residual confounding across the Optum claims population and trial enrollees cannot be fully excluded. Notably, the mRNA-1010 platform's previously demonstrated immunogenicity advantage over high-dose inactivated vaccines in controlled settings provides biological plausibility for a relative effectiveness benefit, since broader antigen coverage and stronger T-cell responses are hallmarks of mRNA formulations. This analysis is best read as hypothesis-generating evidence supporting the case for a prospective, adequately powered head-to-head effectiveness trial — which remains the definitive standard. For a population where influenza hospitalization rates remain stubbornly high, even modest incremental gains in vaccine effectiveness carry substantial public health weight.